Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

Abstract Background The RTS, S/AS01E vaccine provides partial protection against malaria
in African children, but immune responses have only been partially characterized and do not …

In a major public health milestone, European regulators have for the first time delivered a
positive scientific opinion of a vaccine against malaria. The European Medicines Agency …

Background Controlled infection studies in malaria-naive adults suggest increased vaccine
efficacy for fractional-dose versus full-dose regimens of RTS, S/AS01. We report first results …

RTS, S is a novel pre-erythrocytic malaria vaccine based on the circumsporozoite surface
protein (CSP) of Plasmodium falciparum linked to hepatitis B surface antigen (HBs) and …

Background Vaccination and naturally acquired immunity against microbial pathogens may
have complex interactions that influence disease outcomes. To date, only vaccine-specific …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

Development of an effective malaria vaccine that could be deployed widely in endemic
areas has proved to be more difficult than was anticipated, when the first clinical trials of …

The goal of the Malaria Vaccine Program at the Walter Reed Army Institute of Research
(WRAIR) is to develop a licensed multi-antigen, multi-stage vaccine against Plasmodium …

Control measures have significantly reduced malaria morbidity and mortality in the last two
decades; however, the downward trends have stalled and have become complicated by the …